LPT
Financiado
LPT Laser based Proton Therapy sysLPT Laser based Proton Therapy system Har...
LPT Laser based Proton Therapy sysLPT Laser based Proton Therapy system Harnessing High Intensity Lasers Physics for Cancer Treatment Proton Therapy
Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030.
Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have sh...
Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030.
Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown
proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck,
central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery.
Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy
cancer cells. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the
systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical
demand.
LPT is developing a proton therapy system that overcomes the presented challenges, saving up to 50% space and reducing
costs by up to 75%. LPT applies a patented approach to particle acceleration and beam delivery, combining nanotechnology
with Nobel- Prizewinning ultra-high-intensity lasers and advanced magnetics. These technological breakthroughs
enable meaningful reduction
in the size, complexity and cost of proton therapy systems that will enable the widespread adoption of proton therapy both
across Europe and globally.
The technology is supported by the Horizon 2020, SME instrument. The LPT project aims to take the innovation to the next
level through the collaboration of strong industrial and academia players. Together, HIL applied medical, THALES
Optronique and INFN, will achieve fundamental milestones in the development of the commercial system, namely PT-100.
This system will be constructed based on the Alpha system (developed with the support of SME instrument), with a higher
repetition rate and proton flux to enable clinical use and wide market adoption.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2020-11-05
Fecha Fin: 2022-11-30
Fecha Fin: 2022-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-FTI-2018-2020:
Fast Track to Innovation (FTI)
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
HIL APPLIED MEDICAL LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
207.47K€ |
Participante
756.23K€ |
Participante